UFP Technologies, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; interim financial statements are unaudited. UFP Technologies designs and manufactures converted foam, plastic, composite, and natural-fiber products. It reports one operating segment.
Financial performance and position
- Revenue: $34.5 million, up 1.5% from $34.0 million in Q1 2015.
- Profitability: Gross profit was $7.7 million versus $8.6 million; gross margin fell to 22.4% from 25.4%. Operating income declined to $1.7 million from $2.6 million, and net income to $1.1 million from $1.7 million. Diluted EPS was $0.15 versus $0.23.
- Cash flow: Operating cash use was $2.4 million, compared with $1.2 million used in Q1 2015. Investing cash use was $1.6 million, down from $8.5 million, primarily reflecting lower capital spending. Financing cash use was $0.3 million. Cash decreased $4.3 million during the quarter to $25.5 million.
- Liquidity and debt: Current assets were $62.4 million and current liabilities $8.8 million at March 31. Total debt was approximately $1.6 million; there were no borrowings on the $40 million revolving facility, and the company reported covenant compliance. Cash exceeded debt by approximately $23.8 million.
- Balance sheet: Total assets were $119.0 million, total liabilities $14.2 million, and stockholders’ equity $104.8 million.
Material changes versus Q1 2015
- Medical-market sales rose 13.3% to $15.7 million and represented 45.4% of sales. Automotive sales fell 17.6% to $6.1 million. Consumer sales increased; sales in electronics, industrial, and aerospace and defense markets decreased.
- Lower earnings and gross margin primarily reflected consolidation-related material use, labor, training, and customer requalification costs. SG&A declined about 2% to $5.9 million.
- Net interest shifted from $24,000 expense to $11,000 income. The effective tax rate increased to 37.3% from 35.0%, including an approximately $40,000 tax assessment.
- Receivables increased $2.9 million and accrued expenses decreased $2.0 million, contributing to operating cash use. Capital expenditures were $1.6 million versus $8.5 million a year earlier.
Outlook, commentary, and risks
- Management said medical growth was offsetting softness in automotive and aerospace and defense. It expected consolidation-related manufacturing inefficiencies to ease over the next two quarters and the Georgetown-to-Newburyport equipment transfer to finish by the end of Q2 2016.
- Massachusetts consolidations were expected to incur approximately $2.1 million in one-time costs, including $2.0 million of estimated cash charges; approximately $1.8 million had been incurred through March 31. Management estimated annual savings of approximately $1.0 million. The Georgetown relocation was expected to be complete by June 30, 2016.
- The company planned further capacity additions in 2016 and might expand Newburyport or pursue acquisitions. Management believed available resources, expected operating cash, and financing access would meet requirements for the next 12 months, but cautioned that future liquidity depends on operating performance. No specific revenue or earnings guidance was provided.
- Risks highlighted include consolidation execution and savings, new customer contracts, equipment installation and utilization, acquisition identification and integration, and uncertain future cash generation. Management reported no material change in previously disclosed risk factors, market risks, or contractual obligations. There were no off-balance-sheet arrangements other than operating leases.
- The $10 million share-repurchase authorization had approximately $9.4 million remaining; no shares were repurchased in Q1 2016. Disclosure controls were deemed effective, with no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether consolidation costs and production inefficiencies decline as management expects, and whether the estimated $1.0 million annual savings are realized.
- Whether medical-market growth can continue to offset weakness in automotive and aerospace and defense.
- Whether receivables and prepaid expenses normalize and operating cash flow improves after the quarter’s $2.4 million cash use.
- Progress on the Georgetown relocation, Newburyport capacity plans, and related capital spending.
- Future realization of deferred tax assets and any effect of the tax assessment or changes in taxable-income estimates.